MEASURING BIOMARKERS AT EVERY STAGE OF TUMOR DEVELOPMENT
The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research.
Simoa assays have the potential to be used to monitor cancer risk, identify early-stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression-free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions.
Available for Scientific Research
|c-MET||CA 19-9||CA-125||CCL-11/ Eotaxin Assay Kit||CEA|
|CXCL13||Cytokine 3-Plex A TNFα, IL-6, IL-10||G-CSF||GM-CSF||GM-CSF (mouse)|